CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 14 enrolled
Drug / intervention
Oral Alcohol Challengedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04251221
NCT04251221Early Ph 1Completed
CompareCT.gov

Measuring the Neuroimmune Response to Alcohol

Yale University·interventional·Posted Jan 31, 2020·Updated Nov 7, 2023

In Brief

A Early Phase 1 clinical trial evaluating Oral Alcohol Challenge for Alcohol Drinking. Completed, enrolled 14 participants across 1 site.

Detailed Summary

This study uses positron emission tomography imaging of the 18-kDa translocator protein to measure the brain's immune response to alcohol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Drinking
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedJan 31, 2020
Enrollment StartJun 20, 2019
Primary CompletionNov 20, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.4 years ago

Interventions

Oral Alcohol Challengedrug

Subjects will drink an alcohol dose designed to achieve a BAL of 0.08